Samuel Pawel

Samuel Pawel

Auto-generated profile, based on publicly available information

Samuel Pawel

Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Psychological Methods
Verified
Journal Article
Open access
BSBjörn S. Siepe
Björn S. Siepe
FBFrantišek Bartoš
František Bartoš
TMTim P. Morris
Tim P. Morris
ABAnne-Laure Boulesteix
Anne-Laure Boulesteix
DHDaniel W. Heck
Daniel W. Heck
SPSamuel Pawel
Samuel Pawel
Simulation studies are widely used for evaluating the performance of statistical methods in psychology. However, the quality of simulation studies can vary widely in terms of their design, execution, and reporting. In order to assess the quality of typical simulation studies in psychology, we reviewed 321 articles published in Psychological Methods, Behavior Research Methods, and Multivariate Behavioral Research in 2021 and 2022, among which 100/321 = 31.2% report a simulation study. We find that many articles do not provide complete and transparent information about key aspects of the study, such as justifications for the number of simulation repetitions, Monte Carlo uncertainty estimates, or code and data to reproduce the simulation studies. To address this problem, we provide a summary of the ADEMP (aims, data-generating mechanism, estimands and other targets, methods, performance measures) design and reporting framework from Morris et al. (2019) adapted to simulation studies in psychology. Based on this framework, we provide ADEMP-PreReg, a step-by-step template for researchers to use when designing, potentially preregistering, and reporting their simulation studies. We give formulae for estimating common performance measures, their Monte Carlo standard errors, and for calculating the number of simulation repetitions to achieve a desired Monte Carlo standard error. Finally, we give a detailed tutorial on how to apply the ADEMP framework in practice using an example simulation study on the evaluation of methods for the analysis of pre-post measurement experiments. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

8 March 2023 in Biometrical Journal
Verified
Journal Article
Open access
SPSamuel Pawel
Samuel Pawel
LKLucas Kook
Lucas Kook
KRKelly Reeve
Kelly Reeve
Comparative simulation studies are workhorse tools for benchmarking statistical methods. As with other empirical studies, the success of simulation studies hinges on the quality of their design, execution, and reporting. If not conducted carefully and transparently, their conclusions may be misleading. In this paper, we discuss various questionable research practices, which may impact the validity of simulation studies, some of which cannot be detected or prevented by the current publication process in statistics journals. To illustrate our point, we invent a novel prediction method with no expected performance gain and benchmark it in a preregistered comparative simulation study. We show how easy it is to make the method appear superior over well‐established competitor methods if questionable research practices are employed. Finally, we provide concrete suggestions for researchers, reviewers, and other academic stakeholders for improving the methodological quality of comparative simulation studies, such as preregistering simulation protocols, incentivizing neutral simulation studies, and code and data sharing.

9 February 2022 in Journal of the Royal Statistical Society Series B: Statistical Methodology
Verified
Journal Article
Open access
PDF file
SPSamuel Pawel
Samuel Pawel
LHLeonhard Held
Leonhard Held
Replication studies are increasingly conducted but there is no established statistical criterion for replication success. We propose a novel approach combining reverse-Bayes analysis with Bayesian hypothesis testing: a sceptical prior is determined for the effect size such that the original finding is no longer convincing in terms of a Bayes factor. This prior is then contrasted to an advocacy prior (the reference posterior of the effect size based on the original study), and replication success is declared if the replication data favour the advocacy over the sceptical prior at a higher level than the original data favoured the sceptical prior over the null hypothesis. The sceptical Bayes factor is the highest level where replication success can be declared. A comparison to existing methods reveals that the sceptical Bayes factor combines several notions of replicability: it ensures that both studies show sufficient evidence against the null and penalises incompatibility of their effect estimates. Analysis of asymptotic properties and error rates, as well as case studies from the Social Sciences Replication Project show the advantages of the method for the assessment of replicability.

22 April 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSamuel Pawel
Samuel Pawel
LHLeonhard Held
Leonhard Held
Throughout the last decade, the so-called replication crisis has stimulated many researchers to conduct large-scale replication projects. With data from four of these projects, we computed probabilistic forecasts of the replication outcomes, which we then evaluated regarding discrimination, calibration and sharpness. A novel model, which can take into account both inflation and heterogeneity of effects, was used and predicted the effect estimate of the replication study with good performance in two of the four data sets. In the other two data sets, predictive performance was still substantially improved compared to the naive model which does not consider inflation and heterogeneity of effects. The results suggest that many of the estimates from the original studies were inflated, possibly caused by publication bias or questionable research practices, and also that some degree of heterogeneity between original and replication effects should be expected. Moreover, the results indicate that the use of statistical significance as the only criterion for replication success may be questionable, since from a predictive viewpoint, non-significant replication results are often compatible with significant results from the original study. The developed statistical methods as well as the data sets are available in the R package ReplicationSuccess.

30 December 2021 in Research Synthesis Methods
Verified
Journal Article
Open access
PDF file
LHLeonhard Held
Leonhard Held
RMRobert Matthews
Robert Matthews
MOManuela Ott
Manuela Ott
SPSamuel Pawel
Samuel Pawel
It is now widely accepted that the standard inferential toolkit used by the scientific research community—null‐hypothesis significance testing (NHST)—is not fit for purpose. Yet despite the threat posed to the scientific enterprise, there is no agreement concerning alternative approaches for evidence assessment. This lack of consensus reflects long‐standing issues concerning Bayesian methods, the principal alternative to NHST. We report on recent work that builds on an approach to inference put forward over 70 years ago to address the well‐known “Problem of Priors” in Bayesian analysis, by reversing the conventional prior‐likelihood‐posterior (“forward”) use of Bayes' theorem. Such Reverse‐Bayes analysis allows priors to be deduced from the likelihood by requiring that the posterior achieve a specified level of credibility. We summarise the technical underpinning of this approach, and show how it opens up new approaches to common inferential challenges, such as assessing the credibility of scientific findings, setting them in appropriate context, estimating the probability of successful replications, and extracting more insight from NHST while reducing the risk of misinterpretation. We argue that Reverse‐Bayes methods have a key role to play in making Bayesian methods more accessible and attractive for evidence assessment and research synthesis. As a running example we consider a recently published meta‐analysis from several randomised controlled trials (RCTs) investigating the association between corticosteroids and mortality in hospitalised patients with COVID‐19.

7 November 2022 in Translational Medicine Communications
Verified
Journal Article
Open access
PDF file
NDNatascha Drude
Natascha Drude
LMLorena Martinez-Gamboa
Lorena Martinez-Gamboa
MDMeggie Danziger
Meggie Danziger
ACAnja Collazo
Anja Collazo
SKSilke Kniffert
Silke Kniffert
UTUlf Toelch
Ulf Toelch
Clinical translation from bench to bedside often remains challenging even despite promising preclinical evidence. Among many drivers like biological complexity or poorly understood disease pathology, preclinical evidence often lacks desired robustness. Reasons include low sample sizes, selective reporting, publication bias, and consequently inflated effect sizes. In this context, there is growing consensus that confirmatory multicenter studies -by weeding out false positives- represent an important step in strengthening and generating preclinical evidence before moving on to clinical research. However, there is little guidance on what such a preclinical confirmatory study entails and when it should be conducted in the research trajectory. To close this gap, we organized a workshop to bring together statisticians, clinicians, preclinical scientists, and meta-researcher to discuss and develop recommendations that are solution-oriented and feasible for practitioners. Herein, we summarize and review current approaches and outline strategies that provide decision-critical guidance on when to start and subsequently how to plan a confirmatory study. We define a set of minimum criteria and strategies to strengthen validity before engaging in a confirmatory preclinical trial, including sample size considerations that take the inherent uncertainty of initial (exploratory) studies into account. Beyond this specific guidance, we highlight knowledge gaps that require further research and discuss the role of confirmatory studies in translational biomedical research. In conclusion, this workshop report highlights the need for close interaction and open and honest debate between statisticians, preclinical scientists, meta-researchers (that conduct research on research), and clinicians already at an early stage of a given preclinical research trajectory.